6.73 USD
+0.26 (+4.02%)
6.5 USD
-0.23 (-3.42%)
Overall XERS gets a fundamental rating of 4 out of 10. We evaluated XERS against 192 industry peers in the Pharmaceuticals industry. XERS has a bad profitability rating. Also its financial health evaluation is rather negative. XERS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
XERS had negative earnings in the past year.
XERS had a positive operating cash flow in the past year.
In the past 5 years XERS always reported negative net income.
In the past 5 years XERS always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of XERS (-4.22%) is better than 72.40% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.05%, XERS belongs to the top of the industry, outperforming 80.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.22% | ||
| ROE | N/A | ||
| ROIC | 3.05% |
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of XERS (3.68%) is better than 78.13% of its industry peers.
Looking at the Gross Margin, with a value of 84.56%, XERS belongs to the top of the industry, outperforming 86.98% of the companies in the same industry.
In the last couple of years the Gross Margin of XERS has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.68% | ||
| PM (TTM) | N/A | ||
| GM | 84.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XERS is destroying value.
XERS has more shares outstanding than it did 1 year ago.
XERS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, XERS has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.38, we must say that XERS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.38, XERS perfoms like the industry average, outperforming 48.96% of the companies in the same industry.
The Debt to FCF ratio of XERS is 22.00, which is on the high side as it means it would take XERS, 22.00 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of XERS (22.00) is better than 73.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 22 | ||
| Altman-Z | 0.38 |
ROIC/WACC0.31
WACC9.84%
2.3 Liquidity
A Current Ratio of 1.93 indicates that XERS should not have too much problems paying its short term obligations.
XERS has a Current ratio of 1.93. This is in the lower half of the industry: XERS underperforms 62.50% of its industry peers.
XERS has a Quick Ratio of 1.35. This is a normal value and indicates that XERS is financially healthy and should not expect problems in meeting its short term obligations.
XERS has a Quick ratio of 1.35. This is in the lower half of the industry: XERS underperforms 68.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 77.78% over the past year.
The Revenue has grown by 42.05% in the past year. This is a very strong growth!
The Revenue has been growing by 137.28% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)42.05%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%37.06%
3.2 Future
The Earnings Per Share is expected to grow by 34.91% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 23.22% on average over the next years. This is a very strong growth
EPS Next Y93.29%
EPS Next 2Y56.04%
EPS Next 3Y42.72%
EPS Next 5Y34.91%
Revenue Next Year42.48%
Revenue Next 2Y30.98%
Revenue Next 3Y25.91%
Revenue Next 5Y23.22%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
XERS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 40.73 indicates a quite expensive valuation of XERS.
70.83% of the companies in the same industry are more expensive than XERS, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 36.20. XERS is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 40.73 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, XERS is valued a bit cheaper than the industry average as 76.56% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, XERS is valued a bit cheaper than the industry average as 74.48% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 111.94 | ||
| EV/EBITDA | 57.91 |
4.3 Compensation for Growth
XERS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as XERS's earnings are expected to grow with 42.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.04%
EPS Next 3Y42.72%
5. Dividend
5.1 Amount
XERS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.73
+0.26 (+4.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners56.87%
Inst Owner Change7.97%
Ins Owners2.77%
Ins Owner Change1.01%
Market Cap1.12B
Revenue(TTM)266.14M
Net Income(TTM)-15.64M
Analysts85
Price Target11.73 (74.29%)
Short Float %9.89%
Short Ratio6.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.83%
Min EPS beat(2)-100%
Max EPS beat(2)64.35%
EPS beat(4)2
Avg EPS beat(4)1.9%
Min EPS beat(4)-100%
Max EPS beat(4)64.35%
EPS beat(8)3
Avg EPS beat(8)-2.73%
EPS beat(12)6
Avg EPS beat(12)5.17%
EPS beat(16)9
Avg EPS beat(16)1.29%
Revenue beat(2)1
Avg Revenue beat(2)3.46%
Min Revenue beat(2)-1.7%
Max Revenue beat(2)8.61%
Revenue beat(4)3
Avg Revenue beat(4)2.66%
Min Revenue beat(4)-1.7%
Max Revenue beat(4)8.61%
Revenue beat(8)5
Avg Revenue beat(8)1.52%
Revenue beat(12)9
Avg Revenue beat(12)3.74%
Revenue beat(16)11
Avg Revenue beat(16)2.82%
PT rev (1m)27.78%
PT rev (3m)27.78%
EPS NQ rev (1m)-20%
EPS NQ rev (3m)12.49%
EPS NY rev (1m)0%
EPS NY rev (3m)62.5%
Revenue NQ rev (1m)1.14%
Revenue NQ rev (3m)1.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 40.73 | ||
| P/S | 4.2 | ||
| P/FCF | 111.94 | ||
| P/OCF | 105.76 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 57.91 |
EPS(TTM)-0.1
EYN/A
EPS(NY)0.17
Fwd EY2.46%
FCF(TTM)0.06
FCFY0.89%
OCF(TTM)0.06
OCFY0.95%
SpS1.6
BVpS-0.01
TBVpS-0.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.22% | ||
| ROE | N/A | ||
| ROCE | 3.86% | ||
| ROIC | 3.05% | ||
| ROICexc | 4.77% | ||
| ROICexgc | 15.89% | ||
| OM | 3.68% | ||
| PM (TTM) | N/A | ||
| GM | 84.56% | ||
| FCFM | 3.75% |
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
F-Score7
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 22 | ||
| Debt/EBITDA | 10.21 | ||
| Cap/Depr | 4.99% | ||
| Cap/Sales | 0.22% | ||
| Interest Coverage | 0.37 | ||
| Cash Conversion | 49.13% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 0.38 |
F-Score7
WACC9.84%
ROIC/WACC0.31
Cap/Depr(3y)9.93%
Cap/Depr(5y)22.72%
Cap/Sales(3y)0.76%
Cap/Sales(5y)1.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y93.29%
EPS Next 2Y56.04%
EPS Next 3Y42.72%
EPS Next 5Y34.91%
Revenue 1Y (TTM)42.05%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%37.06%
Revenue Next Year42.48%
Revenue Next 2Y30.98%
Revenue Next 3Y25.91%
Revenue Next 5Y23.22%
EBIT growth 1Y121.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year223.57%
EBIT Next 3Y64.3%
EBIT Next 5Y46.27%
FCF growth 1Y113.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y114.95%
OCF growth 3YN/A
OCF growth 5YN/A
XERIS BIOPHARMA HOLDINGS INC / XERS FAQ
Can you provide the ChartMill fundamental rating for XERIS BIOPHARMA HOLDINGS INC?
ChartMill assigns a fundamental rating of 4 / 10 to XERS.
What is the valuation status for XERS stock?
ChartMill assigns a valuation rating of 4 / 10 to XERIS BIOPHARMA HOLDINGS INC (XERS). This can be considered as Fairly Valued.
How profitable is XERIS BIOPHARMA HOLDINGS INC (XERS) stock?
XERIS BIOPHARMA HOLDINGS INC (XERS) has a profitability rating of 3 / 10.
Can you provide the financial health for XERS stock?
The financial health rating of XERIS BIOPHARMA HOLDINGS INC (XERS) is 2 / 10.
Can you provide the expected EPS growth for XERS stock?
The Earnings per Share (EPS) of XERIS BIOPHARMA HOLDINGS INC (XERS) is expected to grow by 93.29% in the next year.